WEBULL
WebtradeDownload

Immunocore Holdings (IMCR) Enters Type 1 Diabetes Following Trial Debut And An Undervalued View

Simply Wall St · 1d ago

Immunocore Holdings (NasdaqGS:IMCR) has moved into autoimmune disease with its first type 1 diabetes patient now dosed in a Phase 1 trial of IMC-S118AI, a tissue specific bispecific therapy.

For context, Immunocore Holdings’ share price has eased around 7% over the past month and about 16% over the past quarter, while the 1 year total shareholder return is down roughly 12%. This points to fading momentum even as this new autoimmune program adds a fresh angle to the long term story.

Scan 33 healthcare AI stocks to see how other high-conviction healthcare and immunology plays compare with Immunocore Holdings as this new autoimmune chapter begins.

Immunocore Holdings now has a fresh autoimmune story but a share price that has fallen over multiple time frames. Is that weakness a chance to build a position today, or a reason to stay patient for a lower entry and clearer valuation support?

Most Popular Narrative: 53% Undervalued

On the most followed narrative, Immunocore Holdings screens as materially undervalued, with a fair value of about $62.50 against a last close of $29.40. This puts the focus squarely on how sustainable KIMMTRAK and the broader pipeline story really are.

Momentum in pipeline diversification, progressing late-stage trials in cutaneous melanoma (TEBE-AM, PRISM-MEL) and expanding into infectious and autoimmune diseases, reduces single-product risk and sets the stage for multiple future revenue streams and earnings expansion.

See why 10 investors see Immunocore Holdings as 53% undervalued.

Result: Fair Value of $62.50 (UNDERVALUED)

Still, Immunocore Holdings relies heavily on KIMMTRAK and is increasing R&D spending, so any clinical setback or slower demand could quickly challenge that undervaluation thesis.

Find out about the key risks to this Immunocore Holdings narrative.

Next Steps

Sentiment in this piece leans cautious, yet the data on Immunocore Holdings is more nuanced than a single label suggests. Move quickly, pull up the supporting metrics, and decide whether the 3 key rewards aligns with your own assessment.

Looking for more Immunocore Holdings sized ideas?

If Immunocore Holdings is on your radar, do not stop here. Broaden your watchlist now and give yourself more ways to put capital to work.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.